Hikma Pharmaceuticals Plc Roxane Acquisition Close (4936Q)
February 29 2016 - 8:46AM
UK Regulatory
TIDMHIK
RNS Number : 4936Q
Hikma Pharmaceuticals Plc
29 February 2016
Closing of Acquisition and issue of Consideration Shares
London, 29 February 2016 - Hikma Pharmaceuticals PLC ("Hikma" or
the "Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the
fast growing multinational pharmaceutical group, announced on 28
July 2015 that it had agreed terms to acquire Roxane Laboratories
Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim
Corporation (the "Acquisition").
The Company is pleased to announce that the Acquisition closed
today, following satisfaction of all necessary conditions.
In accordance with the terms of the Acquisition, the Company
issued 40,000,000 new fully paid ordinary shares to Boehringer
Ingelheim Corporation (the "Consideration Shares"), which will
represent approximately 16.71 per cent. of the Company's share
capital immediately following closing of the Acquisition and
Admission (as defined below).
Applications have been made for the Consideration Shares to be
admitted to the premium segment of the Official List of the UKLA
and to be admitted to trading on the London Stock Exchange's main
market for listed securities ("Admission"). It is currently
anticipated that Admission will occur at 7.00a.m. tomorrow.
Further to the announcement on 24 December 2015 noting that Dr.
Gann would be appointed as a non-executive director of Hikma on
closing of the Acquisition, the appointment is effective from the
date of this announcement.
For further details please contact:
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/+44 7776 477050
Zeena Murad, Investor Relations Manager
+44 (0) 20 7399 2768/+44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Branded", "Injectables"
and "Generics", based principally in the Middle East and North
Africa ("MENA"), where it is a market leader, the United States and
Europe. In 2014, Hikma achieved revenues of US$1,489 million and
profit attributable to shareholders of US$299 million.
CITIGROUP GLOBAL MARKETS LIMITED ("CITI"), WHICH IS AUTHORISED
BY THE PRUDENTIAL REGULATION AUTHORITY AND REGULATED BY THE
FINANCIAL CONDUCT AUTHORITY AND THE PRUDENTIAL REGULATION
AUTHORITY, IS ACTING EXCLUSIVELY FOR HIKMA AND NO ONE ELSE IN
CONNECTION WITH THE ACQUISITION AND WILL NOT BE RESPONSIBLE TO
ANYONE OTHER THAN HIKMA FOR PROVIDING THE PROTECTIONS AFFORDED TO
CLIENTS OF CITI OR FOR PROVIDING ADVICE IN RELATION TO THE
ACQUISITION OR ANY OTHER MATTERS REFERRED TO IN THIS ANNOUNCEMENT.
NEITHER CITI NOR ANY OF ITS DIRECTORS, OFFICERS, REPRESENTATIVES,
EMPLOYEES, ADVISERS, AGENTS OR AFFILIATES OWES OR ACCEPTS ANY DUTY,
LIABILITY OR RESPONSIBILITY WHATSOEVER (WHETHER IN CONTRACT, IN
TORT, UNDER STATUTE OR OTHERWISE) TO ANY PERSON WHO IS NOT A CLIENT
OF CITI IN CONNECTION WITH THIS ANNOUNCEMENT, ANY STATEMENT
CONTAINED HEREIN, THE ACQUISITION OR OTHERWISE.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQLLFSVFVIAFIR
(END) Dow Jones Newswires
February 29, 2016 08:46 ET (13:46 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024